<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526616</url>
  </required_header>
  <id_info>
    <org_study_id>2010.31</org_study_id>
    <nct_id>NCT01526616</nct_id>
  </id_info>
  <brief_title>Spironolactone Plus Metformin in Polycystic Ovary Syndrome</brief_title>
  <official_title>Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators examined whether a combined therapy with low-dose spironolactone plus
      metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary
      Syndrome (PCOS) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present prospective, randomized study, we evaluated the efficacy of a combined therapy
      with metformin and low-dose spironolactone as compared to metformin alone on the clinical and
      endocrine-metabolic alterations of PCOS patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin versus Metformin plus low-dose Spironolactone on metabolic parameters of Patients with Polycystic Ovary Syndrome: a randomized study</measure>
    <time_frame>six months</time_frame>
    <description>We evaluated metabolic parameters across anthropometric parameters: height, weight, waist circumference, BMI, glycemia, lipid profile, blood count, coagulation parameters, hepatic and renal function indexes, OGTT and HOMA-IR. The diagnosis of MetS was established according to the ATPIII criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spironolactone versus Metformin plus spironolactone in hyperandrogenism in Polycystic Ovary Syndrome</measure>
    <time_frame>six months</time_frame>
    <description>We evaluated hyperandrogenism across Hirsutism Score, measuring total testosterone, SHBG, Î”4androstenedione, DHEA-S and FAI. All patients underwent ovarian ultrasound examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>850 mg/day twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin plus spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg twice a day for six months</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus Spironolactone</intervention_name>
    <description>Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day</description>
    <arm_group_label>Metformin plus spironolactone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight/obese patients with PCOS

        Exclusion Criteria:

          -  Other causes of hyperandrogenism and

          -  Use of drugs including:

               -  oral contraceptive

               -  anti-hypertensive agents

               -  anti-diabetic drugs

               -  agents for weight loss
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Mazza B. Fruci A. Belfiore, Doctors</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Unit</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>February 3, 2012</last_update_submitted>
  <last_update_submitted_qc>February 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Prof Antonino Belfiore</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>metformin</keyword>
  <keyword>spironolactone</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>hyperandrogenism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

